Publications by authors named "L A Duska"
•Intraosseous hibernomas are rare benign soft tissue tumors most often diagnosed incidentally.•Intraosseous hibernoma imaging characteristics can mimic bone metastases, including sclerosis, PET-avidity, and heterogenous enhancement.•Bone metastases seconadary to primary gynecologic cancers are rare, but present in 1 - 16% of cases.
View Article and Find Full Text PDFObjectives: To elucidate unmet needs in high-risk endometrial cancer (EC), this study described perioperative treatment patterns in Medicare beneficiaries with high-risk EC and quantified the impact of disease recurrence on clinical and economic outcomes among patients receiving adjuvant therapy.
Methods: Patients aged ≥66 years with high-risk EC (stage I/II EC of non-endometrioid histology or stage III/IVA EC of any histology) receiving hysterectomy with bilateral salpingo-oophorectomy from SEER-Medicare data (2007-2019) were identified; perioperative treatment patterns were described. Post-operative treatment patterns were described among patients receiving adjuvant therapy; overall survival (OS), all-cause and EC-related healthcare resource utilization and costs were evaluated from recurrence date (using a claims-based algorithm developed with clinical input) for recurrent patients and from a frequency-matched date for non-recurrent patients.
Purpose: We assessed the efficacy of cediranib, olaparib, and cediranib/olaparib compared with standard-of-care chemotherapy (SOC) in platinum-resistant or platinum-refractory epithelial ovarian cancer (PROC).
Patients And Methods: NRG-GY005 is an open-label, four-arm, phase II/III superiority trial enrolling patients with high-grade serous/endometrioid PROC and one to three previous therapies. Key exclusion criteria included previous receipt of poly(ADP-ribose) polymerase inhibitor or receipt of antiangiogenic therapy in the recurrent setting.
Article Synopsis
- - The phase 3 study ENGOT-cx11/GOG-3047/KEYNOTE-A18 found that adding pembrolizumab to standard chemoradiotherapy significantly improved progression-free survival in patients with advanced cervical cancer during the first interim analysis.
- - In this study, 1060 patients with high-risk cervical cancer were randomly assigned to receive either pembrolizumab or a placebo alongside chemoradiotherapy, with treatment outcomes evaluated at the second interim analysis.
- - The primary outcomes measured were progression-free survival and overall survival, focusing on patient mortality, with safety being a secondary consideration.